Introduction
Deregulated gene expression is a hallmark of cancer and is well documented in B-cell lymphomas. Expression patterning is reflective of the status of the various gene pathways that define cellular phenotype. For example, in activated B-cell (ABC) type diffuse large B-cell lymphoma (DLBCL) the presence of NFkB signatures indicates constitutive activation and biological dependence on this pathway. Likewise, DLBCLs with BCL6 target gene signatures are dependent on BCL6 for their survival. Gene expression is controlled not only by transcription factors but also by the regulatory state of chromatin. Chromatin modifications including cytosine methylation and histone modifications encode crucial DNA sequence-independent (i.e. epigenetic) information. Because chromatin architecture explains in large part how gene expression and cellular phenotypes are controlled, the elucidation of epigenetic mechanism is of great interest. This review highlights and explores how newly discovered mutations in chromatin modifying genes and perturbations in cytosine methylation patterning might contribute to lymphomagenesis.
Disequilibrium of histone methylation marks: a key event in lymphomagenesis?
Enhancer of zeste 2 (EZH2) is a histone methyltransferase component of polycomb repression complex 2 (PRC2) that methylates histone 3 lysine 27 (H3K27). EZH2 plays an essential role in programming pluripotency and self-renewal of embryonic stem cells [1] . During early B-cell development EZH2 is required for VDJ recombination [2] , is subsequently downregulated in mature B cells, but is highly expressed again after Tcell dependent activation in germinal center B cells [3 ] . In germinal center B cells EZH2 binds to genes involved in differentiation and suppressing cell growth and proliferation such as CDKN1A, CDKN1B, and CDKN2A [3 ] . EZH2 targets displayed H3K27 trimethylation and were repressed. Many B-cell EZH2 targets (i.e. TGFb pathway genes) are different from those in embryonic cells [3 ] . By epigenetically silencing these growth suppressive pathways EZH2 might facilitate the emergence of genetic mutations at these stages, which could lead to development of B-cell neoplasms. DLBCLs and follicular lymphomas are derived from cells that have transited the germinal center reaction. EZH2 is often expressed in DLBCL in which it represses its B-cell target genes [3 ] (Fig. 1 ).
Next generation sequencing of a follicular lymphoma patient identified a heterozygous somatic point mutation in EZH2 exon 15, replacing tyrosine 641 with a histidine residue [4 ] . Resequencing of 221 additional follicular lymphoma patients yielded a 7.2% incidence of heterozygous EZH2
Y641 mutations with several amino acids substituting for tyrosine [4 ] . The incidence of EZH2 Y641 point mutations was 12% in another cohort of 221 patients [5 ] . 9.7% of DLBCLs (n ¼ 320) had EZH2 mutations. However, these occurred only in GCB DLBCLs (21.7%) and primary mediastinal B-cell lymphoma (PMBL, 4.2%) [4 ] . Presence of EZH2 mutations did not appear to affect clinical outcome [4 ] . The Y641 residue is located within the EZH2 SET (suppressor of variegation 3-9, enhancer of zeste, . In addition to potential reduction in H3K4me3, loss of MLL2 or other MLL proteins might also fail to demethylate H3K27. In fact, homozygous or hemizygous inactivating mutations of UTX (which is located on the X chromosome) have been identified in multiple myeloma and may represent an alternative way to alter H3K27 methylation in lymphoid malignancies [18] . UTX mutations were mutually exclusive with t(4;14) translocations, which overexpress another histone methyltransferase called multiple myeloma SET domain protein/Wolf-Hirschhorn syndrome candidate 1 (MMSET). In contrast to EZH2 and UTX mutation, MMSET overexpression is associated with reduction in cellular H3K27 methylation [19 ] , as well as with increased H3K36 and H4K20 methylation [19 ,20 ] . These considerations underline the fact that histone-modifying enzymes truly function in an integrated manner, with disruption of one enzyme affecting the actions of many others [17 ] . Notably, approximately 12% of patients with myelodysplastic syndrome or myeloproliferative neoplasms feature mono-allelic or bi-allelic EZH2 loss of function mutations accompanied by a reduction in cellular H3K27me3 [21 ] . Therefore, EZH2 and MLL family proteins may have opposing roles as tumor suppressors and oncogenes in myeloid development and mature B-cells.
Another example of epigenetic cooperativity involves the H3K9 demethylase Jumonji domain-containing 2C (JMJD2C), which is localized near the Janus kinase 2 (JAK2) locus on a region of chromosome 9p24 amplified in PMBL and Hodgkin lymphoma. JMJD2C demethylation of H3K9 and JAK2 phosphorylation of H3Y41 inhibit binding of heterochromatin-silencing protein HP1a [22 ] . Inhibition of JAK2 plus JMJD2C cooperatively increased H3K9 methylation and HP1a heterochromatin foci in PMBL cells [22 ] . One of the loci silenced in this manner was MYC, which is an important downstream mediator of JAK2 and JMJD2C [22 ] . Blockade or silencing of JAK2 and JMJD2C also resulted in enhanced death of PMBL and Hodgkin lymphoma cell lines [22 ] . Collectively these instances offer some of the first proof that disruption of the proposed combinatorial 'histone code ' [17 ] is deleterious for the homeostasis of transcriptional regulation in B-cells and facilitates lymphomagenesis.
Histone acetyltransferases as tumor suppressors in B-cells
Histone lysine residues are acetylated by histone acetyltransferases (HATs). Histone acetylation induces a more 'open' chromatin structure and recruits bromodomain protein 'readers' to facilitate transcriptional activation. At least 1750 proteins in addition to histones are modified by lysine acetylation in leukemia cells [23] , indicating that HATs have broad cellular activities. Several recent studies implicate the HAT proteins CBP and p300 as tumor suppressors in B-cell neoplasms. CBP and p300 function as co-activators of transcription factors and acetylate proteins relevant to lymphomagenesis such as p53, NFkB, BCL6, and Hsp90 [24, 25, 26 ,27]. In lymphoma, heterozygous p300 truncation mutants deleting the lysine acetyltransferase domain were first revealed in the lymphoma cell line RCK8 [28 ] . Truncated p300 disrupted the function of c-Rel, which normally uses p300 as a co-activator [29 ] . P300 is a direct target gene of the transcriptional repressor BCL6, a key lymphoma oncoprotein and BCL6 and p300 levels were inversely correlated in primary DLBCLs [26 ] . BCL6 inhibitors induce p300 protein expression and acetyltransferase activity in DLBCL cells, with subsequent acetylation of p53 (which induces p53 transcriptional functions) and Hsp90 (which suppresses Hsp90 chaperone activity) [26 ] . Blockade of p300 activity in DLBCL cells rescued them from being killed by BCL6 inhibitors [26 ] and lymphoma cells with mutant p300 were resistant to BCL6 inhibitors. Induction of HLA-B associated transcript 3/BCL2-associated athanogene 6 (BAT3), a critical cofactor of p300 required to acetylate p53, was also required for BCL6 inhibitors to kill DLBCL cells [26 ] . Combining BCL6 and HDAC inhibitors led to even higher p300 activity and synergistic killing of lymphoma cells in vitro and in vivo [26 ] . Suppression of p300 either through BCL6 or inactivating mutations thus plays a key role in DLBCL (Fig. 2) .
Resequencing studies in patients with B-cell neoplasms provided definitive evidence that CBP and p300 are bona fide tumor suppressors [ . Conversely, transfecting wild-type p300 into RCK8 cells, which express truncated p300, partially sensitized them to the actions of BCL6 inhibitor. Therefore, the stoichiometry between wild-type alleles and mutant alleles may be important in determining the biological impact of mutant alleles. Importantly, CBP and p300 are not identical in their biological functions and so it is not clear whether their loss of function in DLBCL is completely bio-equivalent. Although Cebbpþ/À mice display hematopoietic defects and eventually develop hematologic tumors, Ep300þ/À do not reproduce either phenotype [32] . CBP and p300 also mediate different effects on the biological output of wingless-type MMTV integration site signaling and other pathways (reviewed in [33] ). Careful study will thus be required to parse out the various mechanisms through which these mutant alleles contribute to lymphomagenesis.
Aberrant DNA methylation patterning in B-cell lymphomas DNA methylation patterning contains much of the epigenetic information that determines the phenotype of normal and malignant cells [34 ] . Along these lines the methylome of multipotent and lineage-committed progenitors revealed numerous differentially methylated regions and a greater burden of methylation associated with lymphoid commitment [35 ] . Hypermethylation of gene regulatory regions is generally associated with silencing and hypomethylation with gene expression [34 ] , although in reality DNA methylation patterning is more complex. For example, hypermethylation of a CpG-rich region within the first intron of BCL6 was reported to maintain high levels of BCL6 expression, at least in part by blocking binding of a negative regulator of this locus (CCCTC-binding factor, CTCF) [36 ] . BCL6 levels decreased in lymphoma cell lines exposed to the DNA methyltransferase inhibitor decitabine [36 ] . Aberrant hypomethylation of intergenic regions can lead to genomic instability and contribute to malignant transformation [34 ] .
DNA methylation profiling studies indicate that cytosine methylation distribution is perturbed in lymphomas vs. , implying breakdown in lymphomas of the epigenetic barrier that separates PRC2 and cytosine methylation in normal B cells. It is not known whether these events are linked to mutations in EZH2 and MLL2, but is intriguing to consider that perturbations in chromatin structure could lead to mislocalization of cytosine methylation and consequent aberrant epigenetic silencing. It has also been speculated that methylation of PRC2 genes in lymphoma could represent oncogenic events occurring during early lymphoid development [39] .
DNA methylation profiling can also used to classify lymphoma subtypes. Integrated DNA methylation and gene expression profiling of 69 DLBCL cases identified 239 genes differentially methylated in ABC vs. GCB DLBCLs, indicating that these are epigenetically distinct entities [37 ] . Differentially methylated genes in ABC and GCB DLBCLs were centered on a TNFa/ cytokine network, implicating differential methylation of these genes as distinguishing ABC and GCB lymphoma biology [37 ] . The 16 most differentially methylated and expressed genes between ABC and GCB predicted DLBCL subtype in an independent cohort of 203 DLBCL cases with 92% accuracy [37 ] . In a different study, comparison of DNA methylation profiles distinguished mediastinal gray zone lymphoma from the related PMBL and Hodgkin lymphomas and revealed small sets of differentially methylated genes associated with each subtype [43 ] . Although requiring further validation, diagnosis of morphologically difficult to distinguish lymphomas may thus be enhanced using DNA methylation biomarkers.
Cytosine methylation profiles of 22 primary mantle cell lymphomas (MCLs) were compared to 10 sets of purified tonsilar naïve B cells. Remarkably, MCLs displayed twice as many aberrantly hypomethylated as hypermethylated loci, suggesting that aberrant loss of methylation is a dominant feature of this disease [ 
Conclusion
Mutations affecting epigenetic and transcriptional modifiers now appear to be an almost universal feature of B-cell lymphomas. Large-scale disruptions of DNA methylation and histone-modification patterning are emerging as a hallmark of these diseases. The challenge for the next years will be to understand the nature of the lymphoma epigenome and the biochemical and biological effects of mutant epigenetic factors. It will also be necessary to ascertain the utility of DNA methylation classifiers as biomarkers for diagnostic accuracy and therapeutic stratification. Because epigenetic marks are potentially reversible, the development of genuine epigenetic-targeted therapy drugs holds great promise. Already agents are emerging that target transcription factors, chromatin modifying enzymes and epigenetic reader proteins (e.g. [49 ,50 ] ). In the long-term such agents might significantly advance the treatment of Bcell lymphomas with less toxicity to the normal immune system and other tissues.
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